‘Living medicine’ created to tackle drug-resistant lung infections
Researchers have designed the first ‘living medicine’ to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria whic1
Researchers have designed the first ‘living medicine’ to treat lung infections. The treatment targets Pseudomonas aeruginosa, a type of bacteria whic1
This Wednesday, the first episode of the second season of the ‘Information that cares for you/Information that cares’ podcast series will go live. Th1
Respiratory allergy affects around 25% of the general population, especially in spring, at the height of the pollen season. We talk to Dr. Joan Bartr1
SARS-CoV-2-induced lung injury can produce epithelial and endothelial lung damage half a year after hospital discharge, especially in patients old1
The Omicron variant that appeared in South Africa in November 2021 displaced the Delta variant in 3-4 weeks in over 100 countries and now represents1
Vaccination against flu and pneumonia is an important preventive measure that helps to stop these acute infections from developing, and thus helps to1
Interview with Dr Catia Cilloniz, a microbiologist and doctor of medicine at the applied research group on respiratory infections and critical illnes1
The study, led by CIBERES, included the participation of IDIBAPS and was published in the Journal of Internal Medicine.
Interview with Dr. Jacobo Sellarés, Head of the Interstitial Lung Disease Working Group. Pulmonology and Respiratory Allergy Service at the Hospital1
A study coordinated by researchers at BCNatal-IDIBAPS, and published by the journal JAMA Cardiology, shows that people born with a low birth weight p1